NASDAQ:LXRX Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis $0.89 -0.06 (-6.21%) As of 10:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lexicon Pharmaceuticals Stock (NASDAQ:LXRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get LXRX alerts:Sign Up Key Stats Today's Range$0.90▼$0.9550-Day Range$0.53▼$0.9552-Week Range$0.28▼$2.45Volume508,985 shsAverage Volume6.80 million shsMarket Capitalization$320.64 millionP/E RatioN/ADividend YieldN/APrice Target$3.67Consensus RatingHold Company OverviewLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Read More… Lexicon Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreLXRX MarketRank™: Lexicon Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 567th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingLexicon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageLexicon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Lexicon Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($0.66) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexicon Pharmaceuticals is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexicon Pharmaceuticals is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexicon Pharmaceuticals has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Lexicon Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.07% of the float of Lexicon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLexicon Pharmaceuticals has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lexicon Pharmaceuticals has recently decreased by 3.27%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLexicon Pharmaceuticals does not currently pay a dividend.Dividend GrowthLexicon Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.07% of the float of Lexicon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLexicon Pharmaceuticals has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lexicon Pharmaceuticals has recently decreased by 3.27%, indicating that investor sentiment is improving. News and Social Media2.0 / 5News Sentiment0.52 News SentimentLexicon Pharmaceuticals has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Lexicon Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for LXRX on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.90% of the stock of Lexicon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.70% of the stock of Lexicon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lexicon Pharmaceuticals' insider trading history. Receive LXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LXRX Stock News HeadlinesWhile institutions own 28% of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), private equity firms are its largest shareholders with 48% ownershipJune 30 at 8:33 PM | finance.yahoo.comLXRX - Lexicon Pharmaceuticals Inc Price vs Fair Value - MorningstarJune 26, 2025 | morningstar.comMA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking office, more than $12 trillion in private investments into America have been “practically committed” on his watch. "Nobody's ever seen numbers like we have," he said, crediting his agenda of tariffs, tax cuts, and deregulation with making the difference. If true, the figure would indeed be astonishing – potentially tripling the roughly $4 trillion in gross private investment the US reported all of last year.July 1 at 2:00 AM | Porter & Company (Ad)Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Buy Rating from HC WainwrightJune 26, 2025 | americanbankingnews.comH.C. Wainwright reiterates buy rating on Lexicon Pharmaceuticals stockJune 24, 2025 | investing.comData Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)June 23, 2025 | globenewswire.comLexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)June 18, 2025 | globenewswire.comLexicon Pharmaceuticals surges 67% following InvestingPro's Fair Value signalJune 8, 2025 | investing.comSee More Headlines LXRX Stock Analysis - Frequently Asked Questions How have LXRX shares performed this year? Lexicon Pharmaceuticals' stock was trading at $0.7385 on January 1st, 2025. Since then, LXRX shares have increased by 28.1% and is now trading at $0.9457. View the best growth stocks for 2025 here. How were Lexicon Pharmaceuticals' earnings last quarter? Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its earnings results on Tuesday, May, 13th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03. The biopharmaceutical company had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.26 million. Lexicon Pharmaceuticals had a negative net margin of 568.04% and a negative trailing twelve-month return on equity of 103.16%. Read the conference call transcript. How do I buy shares of Lexicon Pharmaceuticals? Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lexicon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Moderna (MRNA). Company Calendar Last Earnings5/13/2025Today6/30/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:LXRX Previous SymbolNASDAQ:LEXG CIK1062822 Webwww.lexpharma.com Phone(281) 863-3000Fax281-863-8010Employees140Year Founded1995Price Target and Rating Average Stock Price Target$3.67 High Stock Price Target$6.00 Low Stock Price Target$1.00 Potential Upside/Downside+287.7%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$200.40 million Net Margins-568.04% Pretax Margin-568.04% Return on Equity-103.16% Return on Assets-54.95% Debt Debt-to-Equity Ratio0.48 Current Ratio2.22 Quick Ratio2.22 Sales & Book Value Annual Sales$31.08 million Price / Sales11.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book2.36Miscellaneous Outstanding Shares361,490,000Free Float311,245,000Market Cap$341.86 million OptionableOptionable Beta1.00 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:LXRX) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.